Premium
Starpharma Holdings Adr (QX) (SPHRY)
USOTC
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Starpharma (ASX:SPL) (OTCQX:SPHRY) today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel® condom by the Australian...
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and...
Starpharma (ASX:SPL)(OTCQX:SPHRY) today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®...
Starpharma and Makhteshim Agan in Priostar Agrochemical Collaboration PR Newswire MELBOURNE, Australia and TEL-AVIV, Israel, March 13, 2013 MELBOURNE, Australia and TEL-AVIV, Israel, March 13...
Starpharma Commences Bacterial Vaginosis Prevention Study of VivaGel(R) PR Newswire MELBOURNE, Australia,, Aug. 15, 2011 MELBOURNE, Australia, Aug. 15, 2011 /PRNewswire-Asia/ -- Starpharma...
VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis PR Newswire SYDNEY, May 23, 2011 SYDNEY, May 23, 2011 /PRNewswire/ -- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced...
MELBOURNE, Australia, Feb. 1 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited (ASX:SPLASX:OTCQX:ASX:SPHRY) today announced the signing of a new agreement with Eli Lilly and Company...
MELBOURNE, Australia, Nov. 18 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited (ASX: SPL; OTCQX: SPHRY) is pleased to announce a successful capital raising of A$15.6 million through a...
MELBOURNE, Australia, Sept. 22 /PRNewswire/ -- Starpharma Holdings Limited (ASX:SPLASX:OTCQX:ASX:SPHRY) today announced that it has received notification of the grant in the US of a key patent...
MELBOURNE, Australia, Aug. 4 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited (ASX:SPLASX:OTCQX:ASX:SPHRY) today announced the results of its clinical trial demonstrating that VivaGel...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 1.33333333333 | 0.75 | 0.76 | 0.67 | 3850 | 0.70441558 | CS |
| 4 | 0.19 | 33.3333333333 | 0.57 | 0.76 | 0.57 | 2374 | 0.70004633 | CS |
| 12 | 0.15951 | 26.5633066329 | 0.60049 | 0.76 | 0.5201 | 1587 | 0.65894698 | CS |
| 26 | -0.06 | -7.31707317073 | 0.82 | 0.9419 | 0.5201 | 1834 | 0.73468102 | CS |
| 52 | -0.325 | -29.9539170507 | 1.085 | 1.33 | 0.5201 | 2370 | 0.88799638 | CS |
| 156 | -9.55 | -92.6285160039 | 10.31 | 10.51 | 0.5201 | 2096 | 3.18660808 | CS |
| 260 | -6.99 | -90.1935483871 | 7.75 | 19.87 | 0.5201 | 2369 | 7.34775369 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
